Laurent Dukas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Laurent Dukas has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Beat Thalmann
From the Geriatric University Clinic, Kantonsspital, Basel, Switzerland
1 shared publicationDagmar Birkner‐Binder
From the Geriatric University Clinic, Kantonsspital, Basel, Switzerland
1 shared publicationErich Schacht
Metabolic Bone Disease Unit, Universitätsklinik Balgrist, Zurich, Switzerland
1 shared publicationHannes B. Stähelin
From the Geriatric University Clinic, Kantonsspital, Basel, Switzerland
1 shared publicationHeike A. Bischoff
From the Geriatric University Clinic, Kantonsspital, Basel, Switzerland
1 shared publicationLyn S. Lindpaintner
From the Geriatric University Clinic, Kantonsspital, Basel, Switzerland
1 shared publication
Latest Publications
- 22 January 2004
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 52 (2) , 230-236
Alfacalcidol Reduces the Number of Fallers in a Community‐Dwelling Elderly Population with a Minimum Calcium Intake of More Than 500 Mg Daily
Objectives: To study the effect of alfacalcidol (1α(OH)D 3 ) on fall risk in community‐dwelling elderly men and women. Design: Randomized, double‐blind, placebo‐controlled intervention trial. Setting: Basel, Switzerland. Participants: Three hundred seventy‐eight community‐dwelling elderly (191 women/187 men). Intervention: Participants were randomly assigned to receive 1 μg of alfacalcidol or matched placebo daily for 36 weeks. Measurements: Serum 25‐hydoxyvitamin D 3 (25(OH) D,1,25‐dihydroxyvitamin D 3 (D‐hormone), and intact parathormone (iPTH) levels were measured using radioimmunoassay at baseline and every 12 weeks. Numbers of fallers and falls were assessed using a questionnaire during each study site visit. Dietary calcium intake was assessed at baseline using a food frequency questionnaire. Results: At baseline, participants had, on average, normal vitamin D and D‐hormone serum levels. Over 36 weeks, alfacalcidol treatment was associated with fewer fallers (odds ratio (OR)=0.69, 95% confidence interval (CI)=0.41–1.16) than placebo. In a post hoc subgroups analysis by medians of total calcium intake, this reduction reached significance in alfacalcidol‐treated subjects with a total calcium intake of more than 512 mg/d (OR=0.45, 95% CI=0.21–0.97, P =.042) but not in those who consumed less than 512 mg/d (OR=1.00, 95% CI= 0.47–2.11, P =.998). Alfacalcidol treatment was also, independent of total calcium intake, associated with a significant 37.9% reduction in iPTH serum levels ( P <.0001). No cases of clinically relevant hypercalcemia were observed. Conclusion: Provided a minimal calcium intake of more than 512 mg/d, alfacalcidol treatment significantly and safely reduces number of fallers in an elderly community dwelling population.
- 22 January 2004
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 52 (2) , 230-236
Alfacalcidol Reduces the Number of Fallers in a Community‐Dwelling Elderly Population with a Minimum Calcium Intake of More Than 500 Mg Daily
Objectives: To study the effect of alfacalcidol (1α(OH)D 3 ) on fall risk in community‐dwelling elderly men and women. Design: Randomized, double‐blind, placebo‐controlled intervention trial. Setting: Basel, Switzerland. Participants: Three hundred seventy‐eight community‐dwelling elderly (191 women/187 men). Intervention: Participants were randomly assigned to receive 1 μg of alfacalcidol or matched placebo daily for 36 weeks. Measurements: Serum 25‐hydoxyvitamin D 3 (25(OH) D,1,25‐dihydroxyvitamin D 3 (D‐hormone), and intact parathormone (iPTH) levels were measured using radioimmunoassay at baseline and every 12 weeks. Numbers of fallers and falls were assessed using a questionnaire during each study site visit. Dietary calcium intake was assessed at baseline using a food frequency questionnaire. Results: At baseline, participants had, on average, normal vitamin D and D‐hormone serum levels. Over 36 weeks, alfacalcidol treatment was associated with fewer fallers (odds ratio (OR)=0.69, 95% confidence interval (CI)=0.41–1.16) than placebo. In a post hoc subgroups analysis by medians of total calcium intake, this reduction reached significance in alfacalcidol‐treated subjects with a total calcium intake of more than 512 mg/d (OR=0.45, 95% CI=0.21–0.97, P =.042) but not in those who consumed less than 512 mg/d (OR=1.00, 95% CI= 0.47–2.11, P =.998). Alfacalcidol treatment was also, independent of total calcium intake, associated with a significant 37.9% reduction in iPTH serum levels ( P <.0001). No cases of clinically relevant hypercalcemia were observed. Conclusion: Provided a minimal calcium intake of more than 512 mg/d, alfacalcidol treatment significantly and safely reduces number of fallers in an elderly community dwelling population.